Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

Journal of Patient-Reported Outcomes

Table 5 WPAI:UC scores for the maintenance phase sample at acute and maintenance phase visits

		Baseline		Week 3		Week 8		Month 12			Post hoc comparisons (Bonferroni-adjusted P [α/4])
	N	LS Mean	SE	LS Mean	SE	LS Mean	SE	LS Mean	SE	P	Baseline vs. Week 3	Baseline vs. Week 8	Baseline vs. Month 12	Week 8 vs. Month 12
Absenteeism	260	12.1	1.60	5.2	1.19	2.6	0.78	3.8	0.93	‡	‡	‡	‡	1.0000
Presenteeism	264	32.6	1.62	16.3	1.17	9.6	0.96	13.4	1.44	‡	‡	‡	‡	0.1015
Overall work impairment	260	38.9	1.92	20.1	1.54	11.5	1.24	15.7	1.72	‡	‡	‡	‡	0.2222
Activity impairment	395	38.9	1.36	20.6	1.05	10.7	0.78	15.4	1.17	‡	‡	‡	‡	†

LS least squares, SE standard error, WPAI:UC Work Productivity and Activity Impairment questionnaire for ulcerative colitis
Findings for each outcome are based on mixed-effects models for repeated measures with subject as a random effect and visit as a fixed effect
Week 8 includes early withdrawal visits during the acute phase. “Month 12” includes early withdrawal visits during the maintenance phase
†P < 0.01, ‡P < 0.001